NVCR News and Press, NovoCure Limited From 09/08/23

Presentations include new post-hoc analysis of data from phase 3 LUNAR trial in metastatic non-small cell lung cancer Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Ca...

2023-09-06 14:27:04 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regard...

2023-09-04 09:30:00 ET After its stock fell 31% on Aug. 28, leaving it down by 72% in the last 12 months, NovoCure (NASDAQ: NVCR) shareholders are bound to be quite displeased. The cancer-treating device maker remains unprofitable despite having its Optune portable therapy machine a...

2023-08-31 18:52:06 ET Shares of Novocure (NASDAQ: NVCR) are down 25.9% so far this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence , as the company announced a discouraging update on the phase 3 INNOVATE-3 clinical trial...

2023-08-31 09:55:00 ET On Monday, shares of healthcare company NovoCure (NASDAQ: NVCR) nosedived by a staggering 38%. That was because the company's ovarian cancer treatment failed to demonstrate that it could improve patient survival rates. As a result of the decline, the stock hit...

Novocure (NASDAQ: NVCR) announced today that data from the randomized phase 3 LUNAR clinical trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of metastatic non-small cell lung cancer (NSCLC) following progression on o...

2023-08-29 16:27:46 ET More on NovoCure NovoCure: TTFields' Ovarian Trial Short-Circuits (Rating Downgrade) NovoCure Limited: Record Losses, Falling Margins, And Downward Momentum NovoCure: Uncertain Regulatory Path And Slowing Growth NovoCure Limited ( N...

2023-08-29 05:44:30 ET Summary NovoCure's Tumor Treating Fields technology faces clinical doubt following a failed phase 3 ovarian cancer trial. Despite a strong liquidity position and manageable debt, NVCR lags the S&P 500 by 70%, indicating potential growth challenges. G...

2023-08-28 13:25:50 ET Gainers: Mobile Infrastructure Corp ( OTC:MBIC ) +88% . Hersha Hospitality Trust ( HT ) +56% . GD Culture Group Limited ( GDC ) +45% . Genius Group Limited ( GNS ) +44% . Hawaiian Electric Industries ( HE ) +...

2023-08-28 10:05:32 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) Tech Ruled The First Half Of 2023, The Industry You Need To Watch In The Second Half XLV Vs. VHT: A Head-To-Head Healthcare ETF C...